BAILLIE GIFFORD & CO 13D and 13G filings for Rubius Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-03-03 11:28 am Sale |
2023-02-28 | 13G | Rubius Therapeutics, Inc. RUBY |
BAILLIE GIFFORD & CO | 0 0.000% |
-4,869,126 (Position Closed) |
Filing |
| 2023-01-20 07:32 am Sale |
2022-12-30 | 13G | Rubius Therapeutics, Inc. RUBY |
BAILLIE GIFFORD & CO | 4,869,126 5.390% |
-61,733 (-1.25%) |
Filing |
| 2022-01-26 06:55 am Purchase |
2021-12-31 | 13G | Rubius Therapeutics, Inc. RUBY |
BAILLIE GIFFORD & CO | 4,930,859 5.490% |
220,798 (+4.69%) |
Filing |
| 2021-01-27 12:12 pm Purchase |
2020-12-31 | 13G | Rubius Therapeutics, Inc. RUBY |
BAILLIE GIFFORD & CO | 4,710,061 5.820% |
458,591 (+10.79%) |
Filing |